Cartalax Cycle Overview
The main point
There is no clinically proven Cartalax cycle. The schedules below summarize online research-community practices and provide clear planning math. They are not recommendations for human use.
Cartalax cycle lengths at a glance
Cycle length
8 weeks
Community schedule
2 mg, 3 mg, then 4 mg daily
Total Cartalax
182 mg
20 mg vials
10 vials
Cycle length
12 weeks
Community schedule
2 mg, 3 mg, 4 mg, then 5 mg daily
Total Cartalax
322 mg
20 mg vials
17 vials
Cycle length
16 weeks
Community schedule
12-week schedule, then 5 mg daily for 4 more weeks
Total Cartalax
462 mg
20 mg vials
24 vials
Cycle length
20 days
Community schedule
10 mg daily
Total Cartalax
200 mg
20 mg vials
10 vials
| Cycle length | Community schedule | Total Cartalax | 20 mg vials |
|---|---|---|---|
| 8 weeks | 2 mg, 3 mg, then 4 mg daily | 182 mg | 10 vials |
| 12 weeks | 2 mg, 3 mg, 4 mg, then 5 mg daily | 322 mg | 17 vials |
| 16 weeks | 12-week schedule, then 5 mg daily for 4 more weeks | 462 mg | 24 vials |
| 20 days | 10 mg daily | 200 mg | 10 vials |
Vial totals are rounded up to the next full 20 mg vial. None of these cycle lengths has been validated in a controlled human trial.
For a full review of Cartalax dosage evidence, benefits, side effects, studies, FDA status, and reconstitution calculations, see the Cartalax peptide protocol.
Where Cartalax Cycle Schedules Come From
Community schedules are not clinical protocols
Published Cartalax research used cultured cells. It did not test injectable doses, dose increases, cycle lengths, or time off between cycles in people.
Cartalax is the short peptide Ala-Glu-Asp, also called AED. Its published research focuses mainly on cartilage-related cells, gene expression, and cell aging.
Human stem-cell study
Researchers used 200 ng/mL AED in cultured human mesenchymal stem cells and measured cartilage-related markers.
Rat chondrocyte study
Researchers also used 200 ng/mL AED in cultured rat cartilage cells and measured cell growth.
No cycle comparison
No published study compared 8, 12, and 16-week Cartalax cycles.
No dose conversion
A concentration used in a cell dish cannot be converted directly into an injectable dose for a person.
Cartalax Cycle Supplies Needed
The quantities below match the community cycle tables on this page. They are included for transparent research planning, not as a recommendation to follow the schedules.
Recommended USA Supply
Choose your region
Use discount code SAVE10 at Orbitrex Peptides checkout. See why we love Orbitrex Peptides.
Cartalax
At-Home Blood Test
Research Supplies
Disclosure: supply links may earn PDP a commission at no cost to you.
Cartalax 20 mg Vials
Vial totals use the exact cycle math and round up to the next full vial.
| Cycle Length | Planning Notes |
|---|---|
8 weeks 10 vials | 28 mg + 42 mg + 112 mg = 182 mg. Divide by 20 mg to get 9.1 vials, then round up to 10. |
12 weeks 17 vials | 182 mg through week 8 + 140 mg in weeks 9–12 = 322 mg. Divide by 20 mg to get 16.1, then round up to 17. |
16 weeks 24 vials | 322 mg through week 12 + 140 mg in weeks 13–16 = 462 mg. Divide by 20 mg to get 23.1, then round up to 24. |
10 mg for 20 days 10 vials | 10 mg × 20 days = 200 mg. Divide by 20 mg to get 10 vials. |
8 weeks
10 vials
28 mg + 42 mg + 112 mg = 182 mg. Divide by 20 mg to get 9.1 vials, then round up to 10.
12 weeks
17 vials
182 mg through week 8 + 140 mg in weeks 9–12 = 322 mg. Divide by 20 mg to get 16.1, then round up to 17.
16 weeks
24 vials
322 mg through week 12 + 140 mg in weeks 13–16 = 462 mg. Divide by 20 mg to get 23.1, then round up to 24.
10 mg for 20 days
10 vials
10 mg × 20 days = 200 mg. Divide by 20 mg to get 10 vials.
Single-Use Supply Count
These counts assume one daily entry and one new syringe and prep pad per entry.
| Cycle Length | Planning Notes |
|---|---|
8 weeks 56 of each | 8 weeks × 7 days = 56 daily entries. |
12 weeks 84 of each | 12 weeks × 7 days = 84 daily entries. |
16 weeks 112 of each | 16 weeks × 7 days = 112 daily entries. |
20 days 20 of each | One daily entry for 20 days = 20 total entries. |
8 weeks
56 of each
8 weeks × 7 days = 56 daily entries.
12 weeks
84 of each
12 weeks × 7 days = 84 daily entries.
16 weeks
112 of each
16 weeks × 7 days = 112 daily entries.
20 days
20 of each
One daily entry for 20 days = 20 total entries.
The count does not include replacements for damaged or contaminated supplies.
Round up only for supply planning. Accurate math does not validate an unproven Cartalax cycle.
Companion Supplies & Routine Support
Cartalax Cycle Chart
The main community schedule increases the daily amount in stages. It begins at 2 mg and reaches 5 mg during the final four weeks.
12-week community-reported Cartalax cycle chart
Research and education only; not a clinically established protocol.
Weeks
1–2
Daily amount
2 mg
Days
14
Phase total
28 mg
Running total
28 mg
Weeks
3–4
Daily amount
3 mg
Days
14
Phase total
42 mg
Running total
70 mg
Weeks
5–8
Daily amount
4 mg
Days
28
Phase total
112 mg
Running total
182 mg
Weeks
9–12
Daily amount
5 mg
Days
28
Phase total
140 mg
Running total
322 mg
| Weeks | Daily amount | Days | Phase total | Running total |
|---|---|---|---|---|
| 1–2 | 2 mg | 14 | 28 mg | 28 mg |
| 3–4 | 3 mg | 14 | 42 mg | 70 mg |
| 5–8 | 4 mg | 28 | 112 mg | 182 mg |
| 9–12 | 5 mg | 28 | 140 mg | 322 mg |
The schedule reaches 182 mg at week 8 and 322 mg at week 12. The reason for this exact dose pattern has not been tested in a human Cartalax trial.
The dose increases are a community convention
No published Cartalax study shows that increasing the amount every two weeks improves safety or research outcomes.
Cumulative Cartalax total during the staged cycle
Based on the community-reported schedule; not a validated human protocol.
Checkpoint
End of week 2
Current phase
2 mg daily
Amount since last checkpoint
28 mg
Cumulative total
28 mg
Checkpoint
End of week 4
Current phase
3 mg daily
Amount since last checkpoint
42 mg
Cumulative total
70 mg
Checkpoint
End of week 6
Current phase
4 mg daily
Amount since last checkpoint
56 mg
Cumulative total
126 mg
Checkpoint
End of week 8
Current phase
4 mg daily
Amount since last checkpoint
56 mg
Cumulative total
182 mg
Checkpoint
End of week 10
Current phase
5 mg daily
Amount since last checkpoint
70 mg
Cumulative total
252 mg
Checkpoint
End of week 12
Current phase
5 mg daily
Amount since last checkpoint
70 mg
Cumulative total
322 mg
Checkpoint
End of week 16
Current phase
5 mg daily extension
Amount since last checkpoint
140 mg
Cumulative total
462 mg
| Checkpoint | Current phase | Amount since last checkpoint | Cumulative total |
|---|---|---|---|
| End of week 2 | 2 mg daily | 28 mg | 28 mg |
| End of week 4 | 3 mg daily | 42 mg | 70 mg |
| End of week 6 | 4 mg daily | 56 mg | 126 mg |
| End of week 8 | 4 mg daily | 56 mg | 182 mg |
| End of week 10 | 5 mg daily | 70 mg | 252 mg |
| End of week 12 | 5 mg daily | 70 mg | 322 mg |
| End of week 16 | 5 mg daily extension | 140 mg | 462 mg |
The week-16 total assumes the 5 mg phase continues for four weeks after the main 12-week schedule.
Cumulative exposure is planning math
A higher cumulative total does not prove that a longer cycle works better. No human Cartalax study has compared these exposure levels.
Cartalax Cycle Calendar
The staged community cycle has set phase-change days. Use PepPal to place the schedule on a calendar and keep the planned dates together.
Cartalax cycle phase calendar
Cycle day
Day 1
Week
Week 1
Community schedule event
First phase begins
Daily amount
2 mg
Cycle day
Day 15
Week
Week 3
Community schedule event
Second phase begins
Daily amount
3 mg
Cycle day
Day 29
Week
Week 5
Community schedule event
Third phase begins
Daily amount
4 mg
Cycle day
Day 57
Week
Week 9
Community schedule event
Fourth phase begins
Daily amount
5 mg
Cycle day
Day 84
Week
End of week 12
Community schedule event
Final day of the main schedule
Daily amount
5 mg
Cycle day
Day 85
Week
Week 13
Community schedule event
Calculated extension begins, if included
Daily amount
5 mg
Cycle day
Day 112
Week
End of week 16
Community schedule event
Final day of the extended schedule
Daily amount
5 mg
| Cycle day | Week | Community schedule event | Daily amount |
|---|---|---|---|
| Day 1 | Week 1 | First phase begins | 2 mg |
| Day 15 | Week 3 | Second phase begins | 3 mg |
| Day 29 | Week 5 | Third phase begins | 4 mg |
| Day 57 | Week 9 | Fourth phase begins | 5 mg |
| Day 84 | End of week 12 | Final day of the main schedule | 5 mg |
| Day 85 | Week 13 | Calculated extension begins, if included | 5 mg |
| Day 112 | End of week 16 | Final day of the extended schedule | 5 mg |
These dates are calculated from the community schedule. They are not medically required phase changes.
- 01
Choose the start date
Treat the first calendar date as cycle day one.
- 02
Mark each phase change
Count forward to days 15, 29, and 57 before adding calendar dates.
- 03
Mark the planned end date
Day 56 ends the 8-week schedule, day 84 ends 12 weeks, and day 112 ends 16 weeks.
- 04
Record schedule changes
A pause or interruption changes the calendar even when the planned total stays the same. Update the dates in PepPal so the record stays current.
Cartalax 8-Week Cycle
The 8-week cycle stops after the 4 mg phase. It includes two weeks at 2 mg, two weeks at 3 mg, and four weeks at 4 mg.
Cartalax 8-week community cycle
Weeks
1–2
Daily amount
2 mg
Weekly amount
14 mg
Phase total
28 mg
Weeks
3–4
Daily amount
3 mg
Weekly amount
21 mg
Phase total
42 mg
Weeks
5–8
Daily amount
4 mg
Weekly amount
28 mg
Phase total
112 mg
| Weeks | Daily amount | Weekly amount | Phase total |
|---|---|---|---|
| 1–2 | 2 mg | 14 mg | 28 mg |
| 3–4 | 3 mg | 21 mg | 42 mg |
| 5–8 | 4 mg | 28 mg | 112 mg |
Total for the full 8-week schedule: 182 mg.
8-week vial requirement
182 mg ÷ 20 mg per vial = 9.1 vials. The planning total rounds up to 10 full 20 mg vials.
No published evidence shows that eight weeks is an effective Cartalax cycle. It is simply the shortest complete version of the staged community schedule reviewed here.
Cartalax 12-Week Cycle
The 12-week cycle adds four weeks at 5 mg daily after the 8-week ramp. It is the complete version of the main community schedule.
Cartalax 12-week community cycle
Weeks
1–2
Daily amount
2 mg
Weekly amount
14 mg
Phase total
28 mg
Weeks
3–4
Daily amount
3 mg
Weekly amount
21 mg
Phase total
42 mg
Weeks
5–8
Daily amount
4 mg
Weekly amount
28 mg
Phase total
112 mg
Weeks
9–12
Daily amount
5 mg
Weekly amount
35 mg
Phase total
140 mg
| Weeks | Daily amount | Weekly amount | Phase total |
|---|---|---|---|
| 1–2 | 2 mg | 14 mg | 28 mg |
| 3–4 | 3 mg | 21 mg | 42 mg |
| 5–8 | 4 mg | 28 mg | 112 mg |
| 9–12 | 5 mg | 35 mg | 140 mg |
Total for the full 12-week schedule: 322 mg.
12-week vial requirement
322 mg ÷ 20 mg per vial = 16.1 vials. The planning total rounds up to 17 full 20 mg vials.
Longer does not mean better
No controlled trial shows that extending Cartalax from 8 to 12 weeks improves cartilage, pain, movement, or another human outcome.
Cartalax 16-Week Cycle
The 16-week cycle extends the 5 mg daily phase for four more weeks. This is a calculated extension of the 12-week schedule, not a separate published protocol.
Cartalax 16-week community cycle extension
Weeks
1–2
Daily amount
2 mg
Weekly amount
14 mg
Phase total
28 mg
Weeks
3–4
Daily amount
3 mg
Weekly amount
21 mg
Phase total
42 mg
Weeks
5–8
Daily amount
4 mg
Weekly amount
28 mg
Phase total
112 mg
Weeks
9–12
Daily amount
5 mg
Weekly amount
35 mg
Phase total
140 mg
Weeks
13–16
Daily amount
5 mg
Weekly amount
35 mg
Phase total
140 mg
| Weeks | Daily amount | Weekly amount | Phase total |
|---|---|---|---|
| 1–2 | 2 mg | 14 mg | 28 mg |
| 3–4 | 3 mg | 21 mg | 42 mg |
| 5–8 | 4 mg | 28 mg | 112 mg |
| 9–12 | 5 mg | 35 mg | 140 mg |
| 13–16 | 5 mg | 35 mg | 140 mg |
Total for the full 16-week schedule: 462 mg.
16-week vial requirement
462 mg ÷ 20 mg per vial = 23.1 vials. The planning total rounds up to 24 full 20 mg vials.
The 16-week cycle creates the highest total exposure among the staged schedules. Human long-term safety and repeated Cartalax exposure have not been established.
Cartalax 10 mg for 20 Days
A separate schedule discussed online uses 10 mg per day for 20 days. It does not follow the gradual 2–5 mg schedule used in the longer cycle examples.
Cartalax 20-day schedule math
Daily amount
10 mg
Duration
20 days
Total amount
200 mg
20 mg vials
10 vials
| Daily amount | Duration | Total amount | 20 mg vials |
|---|---|---|---|
| 10 mg | 20 days | 200 mg | 10 vials |
10 mg × 20 days = 200 mg. This is planning math, not evidence that the schedule is safe or effective.
Do not mix oral and injectable schedules
Twenty-day courses also appear in some oral Cartalax product directions. An oral product schedule does not validate injecting 10 mg of pure AED each day.
No controlled injectable study was identified that supports a 10 mg daily amount, a 20-day duration, or a 200 mg total cycle.
Cartalax Cycle Length Comparison
None of the Cartalax cycle lengths has direct human evidence. The main differences are total exposure, number of phases, and required vial count.
8, 12, and 16-week Cartalax cycle comparison
Cycle
8 weeks
Total exposure
182 mg
Difference
Stops after the 4 mg phase
Evidence status
Community-reported
Cycle
12 weeks
Total exposure
322 mg
Difference
Adds four weeks at 5 mg daily
Evidence status
Community-reported
Cycle
16 weeks
Total exposure
462 mg
Difference
Extends the 5 mg phase for four more weeks
Evidence status
Calculated community extension
Cycle
10 mg for 20 days
Total exposure
200 mg
Difference
Uses a higher fixed amount for a shorter period
Evidence status
Commercial and community claim
| Cycle | Total exposure | Difference | Evidence status |
|---|---|---|---|
| 8 weeks | 182 mg | Stops after the 4 mg phase | Community-reported |
| 12 weeks | 322 mg | Adds four weeks at 5 mg daily | Community-reported |
| 16 weeks | 462 mg | Extends the 5 mg phase for four more weeks | Calculated community extension |
| 10 mg for 20 days | 200 mg | Uses a higher fixed amount for a shorter period | Commercial and community claim |
There is no published basis for calling one schedule the best Cartalax cycle.
Lowest staged exposure
The 8-week cycle has the lowest total exposure among the staged schedules, but this does not prove that it is safe.
Full staged schedule
The 12-week cycle completes all four phases of the main community protocol.
Longest extension
The 16-week cycle adds four weeks at the highest listed phase without stronger clinical evidence.
Separate short schedule
The 20-day schedule uses a fixed 10 mg amount and should not be treated as a shortened form of the staged cycle.
Cartalax Cycle Breaks, Pauses, and Schedule Changes
There is no evidence-based Cartalax cycle break. No controlled trial has compared continuous use with time off or measured how long a break should last.
What is known about Cartalax cycle breaks
Question
Is a break required after eight weeks?
Current answer
No published study provides a required break.
Question
Can another cycle begin right away?
Current answer
Human safety data do not support a clear answer.
Question
Does Cartalax build up over time?
Current answer
Human pharmacokinetics and tissue accumulation are unknown.
Question
Is cycling better than continuous exposure?
Current answer
The two approaches have not been compared.
Question
Does a longer break reset tolerance?
Current answer
Tolerance has not been established for Cartalax.
| Question | Current answer |
|---|---|
| Is a break required after eight weeks? | No published study provides a required break. |
| Can another cycle begin right away? | Human safety data do not support a clear answer. |
| Does Cartalax build up over time? | Human pharmacokinetics and tissue accumulation are unknown. |
| Is cycling better than continuous exposure? | The two approaches have not been compared. |
| Does a longer break reset tolerance? | Tolerance has not been established for Cartalax. |
Community break lengths are not proven
Four-week and eight-week breaks may appear in community discussions, but no Cartalax study has shown that either break is needed or effective.
A paused or missed community-schedule day changes the planned total by the amount assigned to that phase. If dates change, update the PepPal calendar rather than doubling a later amount.
Effect of interrupted days on the planned cycle total
Phase
2 mg phase
Amount removed per missed day
2 mg
Example interruption
1 missed day
Change in total
2 mg less
Phase
3 mg phase
Amount removed per missed day
3 mg
Example interruption
2 missed days
Change in total
6 mg less
Phase
4 mg phase
Amount removed per missed day
4 mg
Example interruption
3-day pause
Change in total
12 mg less
Phase
5 mg phase
Amount removed per missed day
5 mg
Example interruption
5-day pause
Change in total
25 mg less
| Phase | Amount removed per missed day | Example interruption | Change in total |
|---|---|---|---|
| 2 mg phase | 2 mg | 1 missed day | 2 mg less |
| 3 mg phase | 3 mg | 2 missed days | 6 mg less |
| 4 mg phase | 4 mg | 3-day pause | 12 mg less |
| 5 mg phase | 5 mg | 5-day pause | 25 mg less |
Do not double a later amount based only on community instructions. No human Cartalax study provides a missed-dose rule.
Two ways an interruption changes cycle math
Planning choice
Keep the original end date
Total exposure
Lower than the original plan
Calendar length
Unchanged
Evidence limit
No study shows how the lower total affects outcomes
Planning choice
Add the paused days to the end
Total exposure
Returns to the original planned total if the same phase amount is used
Calendar length
Longer
Evidence limit
No study validates extending the cycle
| Planning choice | Total exposure | Calendar length | Evidence limit |
|---|---|---|---|
| Keep the original end date | Lower than the original plan | Unchanged | No study shows how the lower total affects outcomes |
| Add the paused days to the end | Returns to the original planned total if the same phase amount is used | Longer | No study validates extending the cycle |
This table explains the math. It does not recommend replacing missed days or extending a cycle.
Calculated Cartalax totals at different stopping points
Stopping point
End of week 4
Schedule included
2 mg and 3 mg phases
Total amount
70 mg
20 mg vials
4 vials
Stopping point
End of week 6
Schedule included
Two weeks of the 4 mg phase added
Total amount
126 mg
20 mg vials
7 vials
Stopping point
End of week 8
Schedule included
Full 4 mg phase completed
Total amount
182 mg
20 mg vials
10 vials
Stopping point
End of week 10
Schedule included
Two weeks of the 5 mg phase added
Total amount
252 mg
20 mg vials
13 vials
Stopping point
End of week 12
Schedule included
Full staged schedule completed
Total amount
322 mg
20 mg vials
17 vials
Stopping point
End of week 14
Schedule included
Two-week 5 mg extension added
Total amount
392 mg
20 mg vials
20 vials
Stopping point
End of week 16
Schedule included
Four-week 5 mg extension added
Total amount
462 mg
20 mg vials
24 vials
| Stopping point | Schedule included | Total amount | 20 mg vials |
|---|---|---|---|
| End of week 4 | 2 mg and 3 mg phases | 70 mg | 4 vials |
| End of week 6 | Two weeks of the 4 mg phase added | 126 mg | 7 vials |
| End of week 8 | Full 4 mg phase completed | 182 mg | 10 vials |
| End of week 10 | Two weeks of the 5 mg phase added | 252 mg | 13 vials |
| End of week 12 | Full staged schedule completed | 322 mg | 17 vials |
| End of week 14 | Two-week 5 mg extension added | 392 mg | 20 vials |
| End of week 16 | Four-week 5 mg extension added | 462 mg | 24 vials |
All vial counts are rounded up to the next full 20 mg vial.
Calculated does not mean validated
The totals can be calculated accurately, but no human study shows that stopping early, extending the cycle, or changing phase lengths improves the outcome.
Cartalax Cycle Vial Math
Cycle planning depends on the total milligrams used across every phase. Each result below is divided by 20 mg and rounded up to a full vial.
Corrected Cartalax 20 mg vial totals
Cycle
8 weeks
Phase calculation
28 mg + 42 mg + 112 mg
Total
182 mg
Vials required
10 vials
Cycle
12 weeks
Phase calculation
182 mg + 140 mg
Total
322 mg
Vials required
17 vials
Cycle
16 weeks
Phase calculation
322 mg + 140 mg
Total
462 mg
Vials required
24 vials
Cycle
10 mg for 20 days
Phase calculation
10 mg × 20 days
Total
200 mg
Vials required
10 vials
| Cycle | Phase calculation | Total | Vials required |
|---|---|---|---|
| 8 weeks | 28 mg + 42 mg + 112 mg | 182 mg | 10 vials |
| 12 weeks | 182 mg + 140 mg | 322 mg | 17 vials |
| 16 weeks | 322 mg + 140 mg | 462 mg | 24 vials |
| 10 mg for 20 days | 10 mg × 20 days | 200 mg | 10 vials |
Do not round vial requirements down. A result of 16.1 vials requires 17 full vials.
Approximate 20 mg vial duration by community phase
Daily amount
2 mg
Mathematical duration
10 days
Full daily amounts
10
Amount remaining
0 mg
Daily amount
3 mg
Mathematical duration
About 6.7 days
Full daily amounts
6
Amount remaining
2 mg
Daily amount
4 mg
Mathematical duration
5 days
Full daily amounts
5
Amount remaining
0 mg
Daily amount
5 mg
Mathematical duration
4 days
Full daily amounts
4
Amount remaining
0 mg
Daily amount
10 mg
Mathematical duration
2 days
Full daily amounts
2
Amount remaining
0 mg
| Daily amount | Mathematical duration | Full daily amounts | Amount remaining |
|---|---|---|---|
| 2 mg | 10 days | 10 | 0 mg |
| 3 mg | About 6.7 days | 6 | 2 mg |
| 4 mg | 5 days | 5 | 0 mg |
| 5 mg | 4 days | 4 | 0 mg |
| 10 mg | 2 days | 2 | 0 mg |
The 3 mg phase does not divide evenly into a 20 mg vial. This can create a remainder when each phase is planned on its own.
Minimum totals compared with phase-by-phase rounding
Cycle
8 weeks
Minimum from total milligrams
10 vials
Phase totals rounded separately
11 vials
Difference
1 vial
Cycle
12 weeks
Minimum from total milligrams
17 vials
Phase totals rounded separately
18 vials
Difference
1 vial
Cycle
16 weeks
Minimum from total milligrams
24 vials
Phase totals rounded separately
25 vials
Difference
1 vial
| Cycle | Minimum from total milligrams | Phase totals rounded separately | Difference |
|---|---|---|---|
| 8 weeks | 10 vials | 11 vials | 1 vial |
| 12 weeks | 17 vials | 18 vials | 1 vial |
| 16 weeks | 24 vials | 25 vials | 1 vial |
Phase-by-phase rounding can overcount because it treats each phase as a separate supply period. The mathematical minimum is based on the full cycle total.
Do not confuse vial planning with storage guidance
Whether material can carry from one phase into the next depends on the exact product, mixing date, storage conditions, and stated use period. The Cartalax protocol covers general handling limits.
Need the full syringe calculation?
For 20 mg reconstitution examples and U-100 syringe conversion tables, see the Cartalax peptide protocol. The cycle page stays focused on duration, total exposure, and vial planning.
View the full Cartalax 20 mg reconstitution and dosage math.
Common Cartalax Cycle Math Errors
Counting only the final phase
A 12-week total must include the 2 mg, 3 mg, 4 mg, and 5 mg phases.
Rounding the vial count down
A total of 16.1 vials requires 17 full vials, not 16.
Using the 8-week total for 12 weeks
The 8-week cycle totals 182 mg. Adding weeks 9–12 raises the total to 322 mg.
Forgetting the extension phase
A 16-week cycle adds another 140 mg during weeks 13–16.
Mixing the two schedules
The 10 mg for 20 days schedule is separate from the staged 2–5 mg cycle.
Treating correct math as clinical evidence
A correct total does not prove that a cycle is safe, effective, or appropriate.
Cartalax Cycle Evidence Limits
The available research cannot show which cycle length produces a benefit. It also cannot show whether increasing the amount over time is useful.
- No controlled human injectable Cartalax cycle was identified.
- No study compared 8, 12, and 16-week schedules.
- No study established a maximum cycle length.
- No human pharmacokinetic study defined how Cartalax behaves over repeated daily exposure.
- No study showed that extending a cycle improves cartilage, pain, or movement.
- No reliable cycle-break length has been established.
- No controlled study validated the 10 mg for 20 days schedule.
- Most published findings come from cultured cells rather than whole joints or clinical outcomes.
More exposure does not mean more benefit
A 16-week cycle uses 280 mg more Cartalax than the 8-week cycle. There is no clinical evidence showing that this extra exposure produces a better result.
Cartalax Cycle Tracking and Supply Planning
A cycle log can reduce date, phase, and vial-count mistakes. PepPal keeps the schedule, calculations, and tracking record together in one place.
Cartalax cycle log template
Date
[Date]
Cycle day
[Day]
Phase
[Weeks 1–2, 3–4, 5–8, or 9–12]
Planned amount
[Amount]
Vial number
[Vial]
Cumulative total
[Running total]
Notes
[Pause, loss, or schedule change]
Date
[Date]
Cycle day
[Day]
Phase
[Phase]
Planned amount
[Amount]
Vial number
[Vial]
Cumulative total
[Running total]
Notes
[Notes]
Date
[Date]
Cycle day
[Day]
Phase
[Phase]
Planned amount
[Amount]
Vial number
[Vial]
Cumulative total
[Running total]
Notes
[Notes]
| Date | Cycle day | Phase | Planned amount | Vial number | Cumulative total | Notes |
|---|---|---|---|---|---|---|
| [Date] | [Day] | [Weeks 1–2, 3–4, 5–8, or 9–12] | [Amount] | [Vial] | [Running total] | [Pause, loss, or schedule change] |
| [Date] | [Day] | [Phase] | [Amount] | [Vial] | [Running total] | [Notes] |
| [Date] | [Day] | [Phase] | [Amount] | [Vial] | [Running total] | [Notes] |
Cycle start date
Record the exact date used as day one.
Phase-change dates
Mark days 15, 29, and 57 for the staged schedule.
Vial record
Record when each vial is opened and which phase it is used in.
Cumulative amount
Keep a running milligram total rather than estimating at the end.
Interruptions
Record missed days, pauses, spills, and schedule changes.
Final total
Compare the actual total with the original cycle plan.
The mathematical minimum covers the exact cycle total. A planning buffer adds supply for normal measuring loss, vial residue, damage, or an unusable vial.
Cartalax cycle vial planning with a 10% buffer
Cycle
8 weeks
Mathematical minimum
10 vials
10% buffer calculation
10 × 1.10 = 11
Buffered total
11 vials
Cycle
12 weeks
Mathematical minimum
17 vials
10% buffer calculation
17 × 1.10 = 18.7
Buffered total
19 vials
Cycle
16 weeks
Mathematical minimum
24 vials
10% buffer calculation
24 × 1.10 = 26.4
Buffered total
27 vials
Cycle
10 mg for 20 days
Mathematical minimum
10 vials
10% buffer calculation
10 × 1.10 = 11
Buffered total
11 vials
| Cycle | Mathematical minimum | 10% buffer calculation | Buffered total |
|---|---|---|---|
| 8 weeks | 10 vials | 10 × 1.10 = 11 | 11 vials |
| 12 weeks | 17 vials | 17 × 1.10 = 18.7 | 19 vials |
| 16 weeks | 24 vials | 24 × 1.10 = 26.4 | 27 vials |
| 10 mg for 20 days | 10 vials | 10 × 1.10 = 11 | 11 vials |
Buffered totals are rounded up to full vials. The buffer is optional supply planning, not extra Cartalax to add to the cycle.
Do not use the buffer as added exposure
Extra supply does not change the community schedule or support using more Cartalax. It only reduces the chance that normal supply loss leaves the planned math incomplete.
Cartalax Cycle Frequently Asked Questions
Q1: How long is a Cartalax cycle?
Online research communities discuss Cartalax cycles lasting 8, 12, or 16 weeks. A separate schedule uses 10 mg daily for 20 days. None has been validated in a controlled human trial.
Q2: What is the main Cartalax cycle schedule?
One community schedule uses 2 mg daily for weeks 1–2, 3 mg for weeks 3–4, 4 mg for weeks 5–8, and 5 mg for weeks 9–12.
Q3: How much Cartalax is used in an 8-week cycle?
The staged 8-week community schedule totals 182 mg. That equals 9.1 of the 20 mg vials, so the planning total rounds up to 10 vials.
Q4: How much Cartalax is used in a 12-week cycle?
The staged 12-week community schedule totals 322 mg. That equals 16.1 of the 20 mg vials, so the planning total rounds up to 17 vials.
Q5: How much Cartalax is used in a 16-week cycle?
A 16-week extension totals 462 mg when the 5 mg phase continues through weeks 13–16. That rounds up to 24 full 20 mg vials.
Q6: How many Cartalax vials are needed for a cycle?
Using 20 mg vials, the staged schedules require 10 vials for eight weeks, 17 for 12 weeks, and 24 for 16 weeks. The 10 mg for 20 days schedule requires 10 vials.
Q7: What is the Cartalax 10 mg for 20 days cycle?
It is a separate commercial and community schedule that totals 200 mg. It was not traced to a controlled human injectable Cartalax study.
Q8: Does Cartalax need to be increased during a cycle?
The main community schedule increases the daily amount over time, but no human study shows that Cartalax must be increased or that this pattern improves safety.
Q9: Is an 8-week or 12-week Cartalax cycle better?
No study has compared them. The 12-week schedule adds 140 mg of total exposure, but there is no clinical evidence showing that it produces a better outcome.
Q10: Is a 16-week Cartalax cycle better than eight weeks?
There is no evidence that 16 weeks is better. It creates 280 mg more total exposure than the 8-week schedule without added clinical proof.
Q11: How long should the break be between Cartalax cycles?
There is no evidence-based break length. Cartalax studies have not compared different breaks, repeated cycles, or continuous injectable exposure.
Q12: Are Cartalax cycle vial totals often calculated incorrectly?
Yes. A 12-week staged cycle totals 322 mg, not 182 mg. A 16-week extension totals 462 mg. Each vial count must also be rounded up to a full 20 mg vial.
Q13: Does a longer Cartalax cycle produce better results?
No controlled human evidence shows that a longer cycle produces better cartilage, pain, movement, or joint outcomes.
Q14: Where can I find Cartalax reconstitution math?
The Cartalax peptide protocol includes the full 20 mg vial concentration and U-100 syringe calculation tables. This cycle guide focuses on duration, total exposure, and vial requirements.
Q15: Is any Cartalax cycle FDA approved?
No. There is no FDA-approved Cartalax cycle, dose, route, or prescribing label.
Q16: What is the cumulative Cartalax total by week 10?
The total reaches 252 mg by the end of week 10. This is the 182 mg used through week 8 plus 70 mg during the first two weeks of the 5 mg phase.
Q17: On what day does each Cartalax cycle phase change?
The staged community schedule changes on day 15, day 29, and day 57. Day 84 is the final day of the 12-week schedule. These dates can be placed on a PepPal calendar.
Q18: How long does one Cartalax 20 mg vial last?
A 20 mg vial lasts 10 days at 2 mg daily, about 6.7 days at 3 mg, 5 days at 4 mg, and 4 days at 5 mg. These are mathematical values based on the community schedule.
Q19: Why can phase-based vial totals be higher?
Rounding each phase to full vials can leave small remainders and produce a higher total. The mathematical minimum is calculated from the full cycle amount before rounding.
Q20: How does a pause change the Cartalax cycle total?
Each paused day removes the amount assigned to that phase from the planned total. A three-day pause during the 4 mg phase lowers the total by 12 mg unless the schedule is extended. Record changes in PepPal so the calendar stays current.
Q21: Can the Cartalax cycle stop after 10 weeks?
It can be calculated as a 252 mg stopping point, which rounds up to 13 of the 20 mg vials. No study shows whether stopping at week 10 is effective or safer.
Q22: How much does each extra week add after week 12?
Continuing the community schedule at 5 mg daily adds 35 mg for each extra week. Two additional weeks add 70 mg, while four add 140 mg.
Q23: How many daily entries are in each Cartalax cycle?
An 8-week cycle has 56 daily entries, a 12-week cycle has 84, and a 16-week cycle has 112. The separate 20-day schedule has 20 entries. PepPal can keep those entries with the saved cycle plan.
Q24: Should extra Cartalax vials be included for supply loss?
A supply buffer can be calculated for residue, spills, damage, or an unusable vial. It should not be treated as extra Cartalax to add to the planned cycle.
References
- 1. Alanyl-glutamyl-aspartic acid PubChem, National Library of Medicine
- 2. The Influence of Peptides on the Chondrogenic Differentiation of Human Mesenchymal Stem Cells During Replicative Aging Advances in Gerontology (2023)
- 3. Peptides of Cartilage Tissue: Regulation of Chondrocyte Proliferation, Geroprotection and Prospects for Use in Osteoarthrosis Vrach (2023)
- 4. Gene Expression in Human Mesenchymal Stem Cell Aging Cultures: Modulation by Short Peptides Molecular Biology Reports (2020)
- 5. Peptide Regulation of Skin Fibroblast Functions During Their Aging In Vitro Bulletin of Experimental Biology and Medicine (2016)
- 6. Peptide Regulation of Chondrogenic Stem Cell Differentiation International Journal of Molecular Sciences (2023)
Related Dosing Protocols
Educational use only
Peptide Dosing Protocols is an independent educational reference. Nothing here is medical advice or a recommendation for human use. Consult a licensed healthcare provider before considering any compound.
Read the full Cartalax research guide
Review Cartalax dosage evidence, benefits, side effects, studies, FDA status, and full 20 mg vial calculations.
Written by Garret Grant
Founder & Lead Researcher · B.S. Civil Engineering, UCLA
Last updated: August 2026
Human-researched and AI-assisted with full editorial review. I verify sources, protocol interpretation, and final judgments personally. See methodology.
Share this page